Trial Profile
A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms Geometry Mono-1
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 16 Jul 2023 This trial has been completed in Netherlands (Date of the global end of the trial: 16-May-2023), according to the European Clinical Trials Database record.
- 29 Jun 2023 This trial has been completed in France (Date of the global end of the trial: 16-May-2023), according to the European Clinical Trials Database record.